JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Setting

Order Through VWR & Receive a FREE Sample

Support: [email protected]

Track Your Order

Home
Bioactive Compounds

Bioactive Compounds

C7197 3-(Methylthio)propionic acid

≥23 mg/mL
A8193 ABT-737
35 Citation

Summary: BCL-2 protein inhibitor

≥40.67 mg/mL
A4141 Baricitinib (LY3009104, INCB028050)
4 Citation

Summary: JAK1/JAK2 inhibitor,selective orally bioavailable

insoluble in EtOH; insoluble in H2O; ≥18.57 mg/mL
A4097 CUDC-907
2 Citation

Target: Histone Deacetylases (HDACs)|PI3K

Summary: Potent PI3K/HDAC inhibitor

≥25.45 mg/mL
A4100 Droxinostat
2 Citation

Summary: Selective HDAC inhibitor
A8206 Darunavir
2 Citation

Summary: HIV-1 protease inhibitor

≥22.65 mg/mL
A4124 TAK-901

Target: Aurora Kinases|FLT3|Src|JAK|LRRK2|Hck|FGR|YES|Fyn|ARG

Summary: Novel Aurora A/B inhibitor

≥25.25 mg/mL
A4340 Pimobendan

Target: Phosphodiesterases (PDEs)

Summary: Selective PDE3 inhibitor.Ca2+ channel sensitizer

insoluble in H2O; ≥16.2 mg/mL
A4388 XL-888
1 Citation

Target: HSP90

Summary: Hsp90 inhibitor

insoluble in H2O; insoluble in EtOH; ≥18.2 mg/mL
A1501 Mca-Pro-Leu-NH2

Summary: Substrate of matrix metalloproteinases assay